


Distinct metabolic states of a cell guide alternate fates of mutational buffering through altered proteostasis


Verma et al.



Supplementary Figure 1: Strain specific metabolic differences lead to differential mutation buffering capacity (Related to Figure 2)


- A.** Schematic of glycine doublet substitution library (GG) of Gm-R mutants where two consecutive amino acids have been substituted with two glycine residues (red solid filled) starting from 5th amino acid.
- B.** Amino acid sequence alignment of Wt and Gm-R mutants. Residues mutates are shown in red boxes.
- C.** Growth curve for *E. coli* strains CSH4 (black, blue) and WG350 (red, green) in presence and absence of 350 mM NaCl added in excess to the LB medium while growing at 37°C.
- D.** Scatter plot for mean of log₂ of fold change in metabolite concentrations between CSH4 and WG350 against -log₁₀ of p-value. The significantly altered metabolites (2-tailed paired Student's t-test p-value < 0.05, 5 biological replicates for each sample) are shown as colored dots.
- E.** Pathway for production of glycine betaine in *E. coli* showing correlation between metabolomics and transcriptomics. Metabolites upregulated are shown as circular dots and transcripts for the genes are shown as square dots. Color intensity corresponds to fold upregulation.
- F.** Growth of untransformed CSH4(-), WG350(-) and cells transformed with Wt Gm-R and glycine doublet mutant library plasmids (M-Lib) in increasing concentrations of Gentamicin (0-800 µg/ml). Increase in growth is shown as increase in color density.
- G.** Correlation between NGS based quantification of enrichment scores (z-score) and MIC based semi-quantitative activity measurement for Wt Gm-R and mutants I26G, I27G-R28G, V37G-K38G, S39G-K40G of glycine doublet mutant library.
- H.** Histogram for *in vivo* fluorescence of Wt GFP (represented as ratio of GFP/mCherry) in CSH4 (black) and WG350 (red).
- I.** Histograms for ratio of GFP/mCherry fluorescence (left) and independent fluorescence of GFP (middle) and mCherry channel (right) of mutant library Pc in CSH4 and WG350.

(Source data is provided as source data file Supplementary Figure 1)




Supplementary Figure 2: Osmotic stress induced modification in cellular metabolism changes the subset of mutations buffered (Related to Figure 3)

- A.** Scatter plot for \log_2 of fold change in metabolic features between WG350 and CSH4 during osmotic shock against p-value. The significantly different metabolites obtained using 2-sided student's t test ($p\text{-value} < 0.05$, 5 biological replicates for each sample) are represented in colored dots.
- B.** Scatter plot for \log_2 of fold change in metabolic features within strains CSH4 (left) and WG350 (right) on osmotic shock(s) against p-value. The significantly different metabolites ($p\text{-value} < 0.05$, 5 biological replicates for each sample) are represented in colored dots.
- C.** Amino acid sequence alignment of Wt GFP (YeGFP) with the isolated mutants C1, C3 and C6. Mutations are shown in red boxes.
- D.** Histograms for GFP (top panel) and mCherry fluorescence (bottom panel) of the Isolated clones (Wt, C1, C3 and C6 GFP) in WG350 and CSH4 in the presence and absence of 350 mM NaCl.



Supplementary Figure 3: Fluorescence increase is not due to better proteostasis in WG350(S) (Related to Figure 4)

- A.** Mutations buffered in WG350 while growing in 350 mM NaCl (C1, C3, and C6) are marked on the GFP crystal structure (PDB ID: 1GFL) (Yang, Moss and Phillips, 1996). Fluorophore at the centre of the barrel is highlighted in magenta.
- B.** Refolding traces of Wt and GFP mutants obtained on unfolding the proteins in 6 M GuHCl, followed by a 100-fold dilution into Buffer-A (50 mM Tris, 150 mM KCl, 10 mM MgCl₂, 2 mM DTT, pH 7.4) to a final concentration of 200 nM for the proteins. The GFP fluorescence (AU) is plotted against time (s).
- C.** Average thermal melt curves for Wt, C1, C3 and C6 GFP. Fluorescence of each mutants at different temperatures has been normalized to its respective fluorescence at 25°C.
- D.** Schematic of Chloramphenicol-based chase for degradation of GFP as described in Methods. After a short (5 min) induction of GFP with 0.5% arabinose, translation was stalled with Chloramphenicol. Cells were lysed at different points and the amount of intact GFP was monitored by immunoblotting with anti-GFP antibody.
- E.** Plot for the gel-based quantification of intact GFP (left) and representative images for immunoblotting to chase degradation of Wt, C1 and C6 GFP in CSH4 after 5 hr induction of GFP with 0.5% arabinose followed by translation arrest with Chloramphenicol. Ponceau has been used as loading control.
- F.** Representative images from 3 biological replicates for immunoblotting to chase degradation of nascent chains of C1 and C6 GFP as described in Methods in CSH4 and WG350 in presence and absence of osmotic stress. GFP degrades slowest in WG350(S). Ponceau has been used as loading control.
- G.** Representative images from 3 biological replicates for immunoblotting to chase degradation of sGFP in CSH4 and WG350 in presence and absence of osmotic stress. Ponceau has been used as loading control.
- (Source data is provided as source data file Supplementary Figure 3)



Supplementary Figure 4: Observed buffering of GFP mutants is not channelled only through molecular chaperones (Related to Figure 5)

A. Histograms for GFP/mCherry Fluorescence (top panel), GFP (middle panel) and mCherry fluorescence (bottom panel) in absence of overexpressed GroEL/ES (black, red, 2 biological replicates) and while co-expressed with GroEL/ES (blue, green, 2 biological replicates) in CSH4 and WG350. Induction protocol was followed as described in Methods.

B. Histograms for GFP/mCherry Fluorescence (top panel), GFP (middle panel) and mCherry fluorescence (bottom panel) in absence of overexpressed DnaK/J/GrpE (black, red, 2 biological replicates) and while co-expressed with DnaK/J/GrpE (blue, green, 2 biological replicates) in CSH4 and WG350.

C. Bar graph for mean rate of refolding for unfolded Wt GFP in presence and absence of 400 nM DnaK/800 nM DnaJ/400 nM GrpE or 400 nM GroEL/800 nM GroES.

D. Immunoblotting for GFP showing the recruitment of nascently formed C6 GFP into multimeric complexes. Free (or monomeric) GFP are shown with blue box, dimeric GFP are shown in red box and the multimeric complexes are shown in black box. The ratio of GFP in multimeric complex and the amount in monomeric state is shown in the accompanying bar graph.


E. Histograms of GFP or mCherry fluorescence of Wt GFP and pool of GFP mutants having compromised fluorescence (Pc) in BW and molecular chaperone and protease knockout strains ($\Delta dnaj$, $\Delta dnak$, Δtig , Δlon).

F. Representative images from 3 biological replicates for immunoblotting of chase degradation of Wt and C1 GFP in BW, chaperone ($\Delta dnak$), and protease (Δlon) knockout strain. Ponceau has been used as loading control.

G. Heatmaps for growth-based activity of Wt and Gm-R mutant library (lib1, lib2) (top panel), Wt Gm-R and Gm-R mutants (I26G, I27G-R28G) in BW and molecular chaperone knockout strain ($\Delta dnak$) in increasing concentrations of Gentamicin.

(Source data is provided as source data file Supplementary Figure 4)


A



Supplementary Figure 5: Different small molecules affect energetics of folding in a mutant specific manner (Related to Figure 6)

A. Thermal melting profile of Wt, C1, C3 and C6 GFP as mean of change in melting temperature (ΔT_m) in presence of different small molecules. The mean of change in T_m in presence of a small molecule is obtained by subtracting T_m in presence of Buffer-A (50 mM Tris, 150 mM KCl, 10 mM MgCl₂, 2 mM DTT, pH 7.4) from T_m in presence of that respective small molecule (100 mM). Error bars indicate standard deviation among 3 technical replicates.

Suc: Succinate, Sucr: Sucrose, Ala: Alanine, Bet: Betaine, Arg: Arginine, Pro: Proline, Mal: Malate, Malo: Malonate, Ser: Serine, Sor: Sorbitol, Fum: Fumarate, Asp: Aspartate, TMAO: Trimethylamine-N-oxide
(Source data is provided as source data file Supplementary Figure 5)



Supplementary Figure 6: Modification in metabolome due to evolution changes the mutational buffering capacity of the cell (Related to Figure 8)

A. Histograms for fluorescence of Wt and GFP mutants C1 and C6 represented as GFP (left panel) and mCherry fluorescence (right panel) in unevolved BW (WT *E. coli* K12, BW25113) and evolved osmotolerant strains E5, F12, H8.

B. Representative images from 3 biological replicates of Chloramphenicol based chase for checking degradation rates of C1 GFP in BW (WT *E. coli* K12, BW25113) and evolved strains E5, F12, H8. GFP is degraded slower in evolved strains than BW.

C. Chloramphenicol based chase for sGFP in BW (WT *E. coli* K12, BW25113) and evolved strains E5, F12, H8. sGFP is degraded with similar rates in evolved and unevolved BW as shown in densitometric analysis plot at the bottom.

(Source data is provided as source data file Supplementary Figure 6)

Supplementary Table 1: Key resources table

REAGENT	SOURCE	IDENTIFIER
Antibodies		
Anti GroEL (<i>E.coli</i>) mouse monoclonal	ENZO	9A1/2
Anti DnaK (<i>E.coli</i>) mouse monoclonal	ENZO	8E2/2
Anti DnaJ (<i>E.coli</i>) rabbit polyclonal	ENZO	SPA410
Anti Tig (<i>E.coli</i>) rabbit polyclonal	Genescript	A01329
Anti GFP rabbit polyclonal	Abcam	Ab290
Anti RecA rabbit polyclonal	Abcam	Ab125096
Anti Mouse secondary	Santa Cruz Biotechnology	SC2005
Anti Rabbit secondary	Santa Cruz Biotechnology	SC2030
Di(N-succinimidyl) glutarate (DSG)	Sigma	80424
Bacterial and Virus Strains		
<i>E.coli</i> BL21 (DE3)		
<i>E.coli</i> DH5α		
BW (<i>E.coli</i> K12, BW25113) F-, DE(araD-araB)567, lacZ4787(del)::rrnB-3, LAM-, rph-1, DE(rhaD-rhaB)568, hsdR514	(Baba <i>et al.</i> , 2006)	CGSC#: 7636
Δ Tig (JW0426-1) F-, Δ (araD-araB)567, Δ lacZ4787(:rrnB-3), Δ tig-722::kan, λ -, rph-1, Δ (rhaD-rhaB)568, hsdR514	(Baba <i>et al.</i> , 2006)	CGSC#: 8589
Δ dnaK (JW0013-4) F-, Δ (araD-araB)567, Δ lacZ4787(:rrnB-3), λ -, rph-1, Δ dnaK734::kan, Δ (rhaD-rhaB)568, hsdR514	(Baba <i>et al.</i> , 2006)	CGSC#: 8342
Δ dnaJ (JW0014-1) F-, Δ (araD-araB)567, Δ lacZ4787(:rrnB-3), λ -, rph-1, Δ dnaJ735::kan, Δ (rhaD-rhaB)568, hsdR514	(Baba <i>et al.</i> , 2006)	CGSC#: 8343
Δ clpA F-, Δ (araD-araB)567, Δ lacZ4787(:rrnB-3), λ -, Δ clpA783::kan, rph-1, Δ (rhaD-rhaB)568, hsdR514	(Baba <i>et al.</i> , 2006)	CGSC#: 8898
Δ clpP F-, Δ (araD-araB)567, Δ lacZ4787(:rrnB-3), Δ clpP723::kan, λ -, rph-1, Δ (rhaD-rhaB)568, hsdR514	(Baba <i>et al.</i> , 2006)	CGSC#: 8590
Δ clpX F-, Δ (araD-araB)567, Δ lacZ4787(:rrnB-3), Δ clpX724::kan, λ -, rph-1, Δ (rhaD-rhaB)568, hsdR514	(Baba <i>et al.</i> , 2006)	CGSC#: 8591
Δ hslU F-, Δ (araD-araB)567, Δ lacZ4787(:rrnB-3), λ -, rph-1, Δ (rhaD-rhaB)568, Δ hslU790::kan, hsdR514	(Baba <i>et al.</i> , 2006)	CGSC#: 10817

<i>ΔhslV</i> F-, Δ(araD-araB)567, ΔlacZ4787(:rrnB-3), λ-, rph-1, Δ(rhaD-rhaB)568, ΔhslV720::kan, hsdR514	(Baba <i>et al.</i> , 2006)	CGSC#: 10818
<i>ΔsecB</i> F-, Δ(araD-araB)567, ΔlacZ4787(:rrnB-3), λ-, ΔsecB721::kan, rph-1, Δ(rhaD-rhaB)568, hsdR514	(Baba <i>et al.</i> , 2006)	CGSC#: 10640
CSH4 F, lacZ1125, λtrpA49(Am), relA1, rpsL150(strR), spoT	(Newton <i>et al.</i> , 1965)	CGSC#: 8196
WG350 F-, lacZ1125, λ-, Δ(putA-putP)101, trpA49(Am), ΔproU-600, relA1, rpsL150(strR), spoT1, Δ(proP-melB)212	(Culham <i>et al.</i> , 1993)	CGSC#: 8195
Oligonucleotides		
GFP Forward primer (to clone in pET SUMO) CCCGGATCCATGTCTAAAGGTGAAGAATTATTCACGGTGTGTTGTCCCC	This Paper	
GFP Reverse primer (to clone in pET SUMO) CCCAAGCTTTATTGTACAATTCCATCCATA CCATGGGTAATA	This Paper	
GFP Forward primer (to clone in pBAD vector) TGTGCTGAATTCACATATATGTCTAAAGGTGAAGAATTATTCA	This Paper	
GFP Reverse primer (to clone in pBAD vector) ACGGCCAAGCTTTATTGTACAATTCCATCC ATACCATGGG	This Paper	
RBS mCherry Forward primer (to clone in pBAD vector) ACAAAGCTTCCATACCCGTTTTGGGCTAACAGGAGGAATTAAACCATGGTGA	This Paper	
RBS mCherry Reverse primer (to clone in pBAD vector) TCTAAGCTTCTACTTGTACAGCTCGTC	This Paper	
Recombinant DNA		
pOFX ELES (pOFX tac-SL2)	(Castanié <i>et al.</i> , 1997) ⁷⁰	
pOFX DnaK/J/GrpE (pOFX tac-KJE1)	(Castanié <i>et al.</i> , 1997) ⁷⁰	
pET duet1 dnaK	(Tiwari <i>et al.</i> , 2013) ⁷¹	
pET duet1 dnaJ	(Tiwari <i>et al.</i> , 2013) ⁷¹	
pET duet1 grpE	(Tiwari <i>et al.</i> , 2013) ⁷¹	
pET duet1 Mge1	(Tiwari <i>et al.</i> , 2013) ⁷¹	
pET SUMO sGFP	Sadat & Mapa (in process)	
pBAD Gm-R	(Bandyopadhyay <i>et al.</i> , 2012) ²⁵	
pBAD I26G Gm-R	This Paper	

pBAD I27G, R28G Gm-R	This Paper	
pBAD 37G Gm-R	This Paper	
pBAD 39G Gm-R	This Paper	
pET SUMO Wt GFP	This Paper	
pET SUMO C1GFP	This Paper	
pET SUMO C3FP	This Paper	
pET SUMO C6GFP	This Paper	
pBAD Wt GFP mCherry	This Paper	
pBAD C1GFP mCherry	This Paper	
pBAD C3GFP mCherry	This Paper	
pBAD C6GFP mCherry	This Paper	
Software and Algorithms		
Chimera		
Proteowizard	(Brown <i>et al.</i> , 2005) ⁷²	
XCMS	(Smith <i>et al.</i> , 2006; Silva <i>et al.</i> , 2014) ^{73,74}	
Maven	(Lu <i>et al.</i> , 2010; Clasquin, Melamud and Rabinowitz, 2012) ^{65,66}	
FastQC	http://www.citeulike.org/user/nailest/author/Andrews:S	
Trimmomatic	(Bolger, Lohse and Usadel, 2014) ⁶¹	
Kallisto	(Zhang <i>et al.</i> , 2017; Bray <i>et al.</i> , 2016) ^{62,63}	
EBseq	(Leng <i>et al.</i> , 2013) ⁶⁴	
ImageJ		
Origin Pro8		

Supplementary Table 2: List of metabolites along with their \log_2 of fold change and p-values obtained using 2-tailed paired student's t test from untargeted metabolite profiling and analysis using MAVEN platform (Related to Figure 2 and 3)

S.n o.	med Mz	med Rt	Max Quali ty	compoun d	Log ₂ fold change				-Log ₁₀ p-value			
					CSH4 - WG35 0	CSH4 - CSH4 (S)	WG35 0 - WG35 0 (S)	CSH4 (S) - WG35 0 (S)	CSH4-WG350	CSH4-CSH4 (S)	WG350 - WG350 (S)	CSH4 (S) - WG350 (S)
1	363.0344	2.041682	0.848391	N-Acetylputre scine	0.00	-14.03	-14.29	-0.26	0.01	0.97	1.54	0.45
2	283.0684	4.029608	0.849596	Geranyl-PP	0.00	-13.99	-13.89	0.10	0.05	1.67	1.43	0.20
3	151.025	1.858412	0.819399	fructose-1-6-bisphosph ate	0.00	-12.65	0.00	12.65	0.00	2.24	0.43	5.16

4	116. 070 5	2.341 379	0.828 605	succinate	0.00	-11.67	-25.78	-14.11	0.43	1.60	2.15	1.80
5	243. 062 2	2.131 804	0.848 934	UMP	2.10	-4.63	-4.86	1.87	0.49	2.56	1.80	1.80
6	167. 020 4	2.374 183	0.847 362	orotidine- 5-- phosphate	10.98	-4.25	-14.62	0.61	1.12	4.78	1.71	1.38
7	323. 029 1	3.537 884	0.851 401	betaine	-0.93	-4.17	-7.94	-4.70	0.53	0.95	0.98	1.78
8	606. 074 8	4.036 123	0.851 434	Octoluse Bisphosph ate	1.06	-3.88	-4.69	0.24	0.15	1.00	1.04	0.28
9	565. 048 2	4.056 136	0.857 477	tryptophan	0.44	-3.75	-4.18	0.01	0.05	1.93	1.71	0.22
10	402. 994 9	2.973 083	0.849 58	thiamine- phosphate	0.12	-3.73	-2.99	0.87	0.01	1.34	1.15	3.48
11	180. 065 7	2.219 842	0.858 241	fumarate	-2.93	-3.27	-6.82	-6.49	0.88	0.51	3.44	1.03
12	203. 081 9	1.413 762	0.840 261	FMN	1.54	-2.86	-1.06	3.34	1.17	1.98	0.65	4.25
13	203. 081 9	1.505 575	0.858 171	asparagine	-1.04	-2.73	0.10	1.79	0.62	2.12	0.10	3.83
14	341. 108 9	2.038 149	0.846 411	glutathione disulfide	-1.96	-2.52	-0.13	0.43	1.29	1.15	0.39	0.24
15	421. 075 6	1.887 725	0.851 835	CMP	-1.08	-2.37	1.97	3.26	0.47	1.60	1.10	1.82
16	241. 082 7	2.019 653	0.856 852	GMP	1.22	-2.33	-2.11	1.44	1.97	4.11	2.86	3.62
17	344. 069 1	2.006 949	0.846 896	UDP	-0.13	-2.28	-1.68	0.47	0.10	4.33	3.04	0.73
18	424. 039	1.499 295	0.860 667	aspartate	-0.40	-1.99	2.16	3.75	0.64	3.32	2.82	5.07
19	264. 104 5	1.446 013	0.858 174	trehalose/s ucrose	1.55	-1.89	-1.60	1.84	3.11	3.67	2.71	3.08
20	866. 124 9	1.450 47	0.857 708	Cellobiose	1.55	-1.89	-1.60	1.84	3.11	3.67	2.71	3.08
21	117. 018 6	2.093 047	0.854 168	N-Acetyl-L- alanine	-1.80	-1.77	0.08	0.05	0.78	1.01	0.38	0.06
22	171. 006 5	3.843 684	0.849 186	IMP	-0.41	-1.66	-1.07	0.18	0.38	2.09	1.54	0.45
23	253. 009 9	2.067 247	0.861 783	Pyrogluta mic acid	-1.85	-1.53	-0.12	-0.43	0.64	0.67	0.41	0.80
24	368. 998 9	3.985 863	0.849 202	S-methyl- 5-- thioadenos ine	-0.27	-1.28	-1.28	-0.28	0.15	1.34	1.39	0.43
25	266. 070 7	1.685 908	0.833 351	ribose- phosphate	-0.60	-1.15	0.82	1.37	0.75	1.65	1.10	2.80
26	296. 080 6	2.066 397	0.852 619	N-acetyl-L- ornithine	0.30	-1.10	-1.11	0.30	0.35	2.75	2.67	0.64

27	383. 115 2	3.042 196	0.771 733	Acetyllysin e	0.05	-0.96	-0.98	0.04	0.11	1.80	2.12	0.13
28	229. 011 2	2.020 989	0.853 25	adenosine	0.89	-0.91	-1.32	0.48	0.93	2.14	2.15	2.26
29	375. 131	2.323 842	0.847 81	xanthosine -5- phosphate	-0.18	-0.89	-0.73	-0.01	0.04	1.82	2.08	0.03
30	176. 935	4.759 889	0.852 717	2- Isopropylm alic acid	0.23	-0.74	-0.66	0.30	0.24	1.32	1.66	0.68
31	128. 034 1	1.833 35	0.853 449	dCDP	-0.36	-0.47	0.46	0.58	0.07	1.29	0.49	2.60
32	168. 065 6	2.160 493	0.853 901	xanthosine	0.45	-0.45	-0.52	0.37	1.07	1.80	1.32	1.07
33	114. 055 1	10.95 572	0.731 41	p- hydroxybe noate	-0.33	-0.42	-0.22	-0.14	0.67	0.25	1.34	0.49
34	225. 039 2	11.50 664	0.848 89	Sedohepto luse bisphosph ate	-0.26	-0.24	-0.07	-0.09	0.28	0.00	0.14	0.08
35	145. 030 1	1.693 76	0.833 608	cystathioni ne	0.19	-0.23	-1.06	-0.64	0.54	0.38	1.94	0.55
36	218. 102 9	1.981 234	0.860 063	hypoxanthi ne	-0.22	-0.19	-0.01	-0.04	0.52	0.74	0.11	0.03
37	137. 023 2	1.572 158	0.857 927	glutamine	-0.07	-0.16	-0.09	0.00	0.28	0.01	0.07	0.06
38	367. 019 8	1.393 888	0.848 99	UDP-D- glucose	-0.14	-0.14	-0.10	-0.09	0.64	0.59	0.14	0.02
39	131. 081 4	6.987 23	0.856 877	Kynurenin e	0.22	-0.11	-0.34	-0.02	0.22	0.36	1.13	0.16
40	399. 013 1	5.573 004	0.850 927	riboflavin	-0.10	-0.09	-0.13	-0.14	0.07	0.04	0.50	0.29
41	319. 046 3	5.199 954	0.849 735	Thiamine pyrophosp hate	-0.03	-0.09	-0.05	0.01	0.12	0.54	0.56	0.12
42	146. 044 7	5.076 94	0.840 613	Octoluse 8/1P	0.10	-0.08	-0.32	-0.14	0.20	0.50	0.53	0.25
43	742. 069 5	3.301 201	0.735 053	valine	0.22	-0.08	-0.36	-0.06	0.27	0.36	1.11	0.22
44	664. 118	1.939 427	0.662 212	cyclic-AMP	0.27	-0.02	0.62	0.91	0.55	0.64	1.54	1.10
45	662. 102 7	8.182 36	0.852 802	tryptophan	0.28	-0.01	-0.40	-0.11	0.20	0.13	0.99	0.61
46	175. 035 1	1.743 987	0.851 61	glucose-6- phosphate	0.35	0.04	1.96	2.27	0.75	0.07	0.43	3.75
47	129. 102 3	6.072 19	0.850 308	thiamine	0.00	0.05	-0.08	-0.14	0.13	0.05	0.50	0.34
48	173. 092 2	2.708 844	0.814 59	pantothena te	0.40	0.06	-0.53	-0.18	0.33	0.03	1.38	0.97
49	130. 049 8	5.998 872	0.854 558	biotin	0.14	0.06	-0.17	-0.09	0.19	0.08	0.77	0.16

50	187. 071 6	1.777 959	0.832 413	shikimate- 3-phosphate	0.04	0.06	0.20	0.18	0.44	0.47	1.26	0.37
51	188. 055 6	1.504 867	0.772 704	N-acetyl- glutamine	0.04	0.09	0.16	0.10	0.02	0.01	1.50	1.00
52	300. 046 6	1.719 046	0.848 407	guanine	-0.13	0.13	0.24	-0.02	0.45	0.03	0.79	0.22
53	179. 055 2	1.501 844	0.851 44	inosine	-0.21	0.17	1.76	1.37	0.00	0.07	2.49	1.18
54	134. 029 4	2.005 65	0.855 251	dGMP	0.40	0.25	0.12	0.27	0.68	0.33	0.71	0.24
55	148. 042 6	3.287 45	0.850 251	D- sedoheptul ose-1/7- phosphate	0.19	0.26	0.12	0.05	0.03	0.17	0.99	0.45
56	133. 013 1	1.936 306	0.677 158	methionine	-0.17	0.29	0.50	0.05	0.16	1.54	0.85	0.13
57	145. 097 1	1.390 545	0.850 053	UDP-N- acetyl- glucosami ne	-0.21	0.40	0.18	-0.42	0.17	0.40	0.66	0.17
58	205. 034 7	2.536 442	0.851 966	proline	-0.88	0.40	-1.20	-2.48	0.33	0.24	0.81	1.84
59	289. 115 5	1.833 144	0.851 898	α - ketoglutarate	0.38	0.42	1.06	1.02	1.23	1.41	2.15	1.78
60	207. 077	2.012 048	0.833 829	tyrosine	0.15	0.48	0.51	0.18	0.70	2.96	2.09	1.13
61	267. 072 5	1.519 962	0.766 428	Aminoadipi c acid	0.22	0.49	0.01	-0.26	0.38	1.51	0.22	1.52
62	347. 039 5	2.047 51	0.799 432	N-acetyl- glutamate	0.26	0.53	0.47	0.19	0.21	1.07	0.92	0.36
63	135. 030 1	3.948 531	0.850 648	acetyl-CoA	0.12	0.55	1.77	1.34	0.04	2.12	2.55	2.32
64	112. 428 6	1.409 344	0.858 314	arginine	0.12	0.56	0.53	0.09	0.51	1.82	2.03	0.09
65	154. 061 1	1.914 433	0.856 739	glutathione	0.05	0.57	0.97	0.45	0.03	1.40	2.23	1.89
66	282. 086 1	1.459 852	0.857 308	ornithine	-0.04	0.58	0.55	-0.07	0.34	0.41	2.33	0.09
67	150. 041 1	2.037 107	0.853 763	thymidine	0.18	0.59	0.36	-0.04	0.44	1.94	2.04	0.31
8	362. 051 1	1.499 073	0.851 382	L-arginino- succinate	-0.38	0.63	2.28	1.27	0.38	1.49	2.82	0.84
69	611. 140 8	2.658 341	0.853 422	N-acetyl- glucosami ne-1/6- phosphate	0.02	0.67	0.51	-0.14	0.21	2.95	2.74	0.61
70	306. 076 5	1.728 165	0.823 201	N- carbamoyl- L- aspartate	0.61	0.73	0.23	0.11	0.87	0.40	0.17	0.02
71	145. 060 7	2.068 78	0.715 853	uridine	0.12	0.75	0.56	-0.06	0.21	2.06	1.65	0.42

72	259. 022	1.509 566	0.783 648	pyridoxine	-0.08	0.76	0.58	-0.26	0.11	3.64	3.39	2.73
73	178. 071 4	1.853 829	0.854 485	sn-glycerol-3-phosphate	0.08	0.83	0.36	-0.39	0.00	2.49	1.50	1.29
74	177. 039 5	2.047 71	0.750 985	xanthine	-0.02	0.84	0.62	-0.24	0.23	2.54	2.09	1.04
75	313. 058 9	2.024 257	0.820 586	citrate/isocitrate	0.48	0.85	0.79	0.42	0.68	1.42	1.53	1.24
76	109. 526 4	1.386 311	0.855 701	adenosine 5'-phosphosulfate	0.31	0.85	0.50	-0.04	0.53	2.48	2.30	0.33
77	338. 989	1.485 925	0.818 313	O-acetyl-L-serine	-0.14	0.93	0.85	-0.22	0.73	3.92	3.35	1.01
78	455. 101 4	6.339 029	0.859 511	2,3-dihydroxybenzoic acid	-1.45	0.94	-0.60	-2.99	2.03	1.58	1.11	3.67
79	784. 150 8	1.505 536	0.850 999	cytidine	-0.05	0.96	0.86	-0.15	0.01	4.59	3.03	0.30
80	321. 049 6	1.780 281	0.860 946	malate	-0.10	0.99	0.15	-0.95	0.12	1.90	0.05	4.07
81	346. 055 8	1.441 355	0.856 271	lysine	1.42	1.02	-0.06	0.34	1.83	1.76	0.14	1.05
82	686. 142 3	1.567 711	0.853 065	lipoate	0.04	1.08	0.61	-0.43	0.38	3.09	2.51	2.90
83	251. 077 6	4.043 802	0.849 58	FAD	-0.14	1.11	0.56	-0.69	0.23	3.17	0.87	1.06
84	250. 093 7	2.100 759	0.846 352	NADP+	0.30	1.11	1.08	0.27	0.04	0.65	1.58	0.25
85	386. 017 2	1.486 119	0.856 649	D-gluconate	-0.02	1.15	1.23	0.05	0.30	2.63	3.13	0.20
86	289. 035 2	1.507 047	0.851 621	2-dehydro-D-gluconate	-0.21	1.28	1.75	0.27	0.04	2.48	1.42	0.27
87	258. 037 5	1.453 563	0.828 056	histidine	0.30	1.30	1.00	0.01	0.46	2.73	3.55	0.11
88	195. 050 2	2.024 109	0.852 796	dTMP	-0.94	1.31	1.59	-0.66	1.19	1.38	2.20	1.03
89	199. 000 7	1.550 444	0.856 554	homoserine	-2.41	1.32	-1.46	-5.18	0.76	0.25	0.97	1.45
90	242. 078	2.027 355	0.788 688	glucono- γ -lactone	0.47	1.33	1.05	0.18	0.65	2.37	1.75	0.20
91	239. 014 7	1.507 822	0.829 343	myo-inositol	-0.17	1.38	1.11	-0.44	0.91	4.50	3.63	1.23
92	221. 059 8	1.489 268	0.854 986	citrulline	-0.20	1.46	1.22	-0.43	0.35	3.66	2.77	1.07
93	328. 045 4	3.954 113	0.838 432	succinyl-CoA/methylmalonyl-CoA	-0.26	1.66	1.51	-0.42	0.34	1.03	2.36	0.81
94	689. 087 7	2.038 819	0.852 447	cyclic bis(3->5-)dimeric GMP	-0.18	1.68	1.61	-0.24	2.83	3.02	2.29	0.14

95	766. 109 1	1.525 817	0.835 367	Phenylpro- picolic acid	0.14	1.75	1.23	-0.37	0.00	0.58	1.85	0.47
96	322. 044 5	3.260 484	0.848 054	coenzyme A	-1.70	1.77	1.48	-1.99	1.48	2.14	1.76	3.87
97	174. 087 4	1.793 035	0.851 756	D- erythrose- 4- phosphate	0.19	1.89	1.83	0.14	0.42	1.66	1.94	0.01
98	191. 019	1.979 981	0.851 608	Methylcyst- eine	0.95	2.07	1.70	0.58	0.58	1.09	0.71	0.54
99	341. 108 9	1.499 742	0.852 927	S-ribosyl- L- homocyste- ine-nega	0.12	2.14	0.40	-1.63	0.11	2.81	0.72	1.16
100	243. 080 4	1.504 422	0.852 072	deoxyinosi- ne	0.31	2.21	1.33	-0.57	0.79	2.89	2.21	0.13
101	116. 071 1	1.985 581	0.853 67	NADH	-2.59	2.54	3.62	-1.52	1.44	0.68	3.51	0.63
102	132. 029 1	1.759 809	0.850 709	trehalose- 6- Phosphate	2.73	2.56	0.30	0.47	3.62	3.26	0.95	2.36
103	131. 045	1.469 88	0.853 972	deoxyaden- osine	0.33	2.69	1.93	-0.43	0.47	4.44	2.27	0.21
104	173. 103 5	1.516 454	0.850 518	D- glucosami- ne-6- phosphate	0.68	2.77	1.61	-0.49	0.69	1.86	0.67	0.30
105	160. 060 5	1.466 613	0.852 018	glucosami- ne	0.42	2.83	2.92	0.51	0.89	3.49	2.96	0.18
106	426. 012 1	2.080 937	0.848 104	NAD+	-0.69	3.58	2.11	-2.15	0.07	2.46	0.79	1.78
107	266. 091	1.819 532	0.852 153	Pyrophosp- hate	0.22	4.02	3.37	-0.43	0.55	5.90	4.13	0.82
108	187. 108	1.889 188	0.850 813	Uric acid	-0.31	4.32	3.55	-1.08	0.17	4.38	2.87	0.74
109	808. 119 6	2.336 574	0.830 013	dephospho- -CoA	-1.36	11.89	2.10	-11.15	1.16	1.83	1.11	0.44
110	145. 013 2	2.367 599	0.838 086	Cystine	1.04	12.24	11.20	0.00	2.09	7.53	1.86	0.43
111	153. 018 2	1.509 54	0.803 857	S-adenosyl- L- homoCyst- eine	-0.86	12.98	13.85	0.00	1.67	8.01	6.35	#DIV/0!
112	175. 060 2	1.598 831	0.850 469	prephenat- e	0.46	13.61	13.14	0.00	0.07	5.34	1.52	0.75
113	193. 034 6	1.511 09	0.831 777	guanosine	0.08	14.42	1.34	-13.00	0.45	1.36	2.89	1.14

Key: med Mz: Median *m/z* for metabolites, medRt: Median Retention Time, Max Quality: quality of peaks detected, compound: Metabolite, CSH4 - WG350: log₂ of fold change and between CSH4 and WG350, CSH4 - CSH4 (S): log₂ of fold change between CSH4 and CSH4 salt, WG350 - WG350 (S): log₂ of fold change between WG350 and WG350 salt, CSH4 (S)- WG350 (S): log₂ of fold change between CSH4 salt and WG350 salt

Supplementary Table 3: ODEs used for the kinetic simulations. (Related to figure 4)

Numerical simulation was set up with a fixed concentration of mRNA/ribosome complex (S). These complexes could either form nascent polypeptides (U) with a rate k_{trans} that is a collective rate constant for transcription/translation, or be inhibited with a rate constant k_{block} in the presence of a translation inhibitor (I). The pool of U could either degrade with a rate k_{deg} or fold with a rate constant of k_f and reach the native state (F). We finally monitor the total amount of undegraded protein (U+F) after blocking translation after 300 s of starting the simulation (simulation start mimics induction). The reaction volume was kept at 1 liter.

ODEs:

$$d(U)/dt = -\text{ReactionFlux1} - \text{ReactionFlux2} + \text{ReactionFlux3}$$

$$d(F)/dt = \text{ReactionFlux1}$$

$$d(S)/dt = -\text{ReactionFlux3} - \text{ReactionFlux4}$$

$$d(B)/dt = \text{ReactionFlux4}$$

$$d(I)/dt = -\text{ReactionFlux4}$$

Fluxes:

$$\text{ReactionFlux1} = k_f * U$$

$$\text{ReactionFlux2} = k_d * U$$

$$\text{ReactionFlux3} = k_{trans} * S$$

$$\text{ReactionFlux4} = k_i * S * I$$

Parameter Values:

$$k_f = 0.02 \text{ (s-1)}$$

$$k_{deg} = 0.01 \text{ (s-1)}$$

$$k_{trans} = 0.001 \text{ (s-1)}$$

$$k_i = 0.0001 \text{ (M-1s-1)}$$

$$\text{cell volume} = 1 \text{ (liters)}$$

Initial Conditions (micromoles):

$$U = 0$$

$$F = 0$$

$$S = 1000$$

B = 0

I = 0

Dosing:

Delay: 300 s

1 mM of I added to reaction

Supplementary Table 4: Concentration of metabolites added to LB to measure effect of metabolites on Fluorescence *in vivo* (Related to Figure 7)

S. no.	Metabolite	Concentration (mM)
1	Alanine	200
2	Arginine	2.5
3	Betaine	200
4	Proline	200
5	Serine	200
6	TMAO	200
7	Aspartate	200
8	Malate	100
9	Malonate	100
10	Fumarate	100
11	Succinate	100
12	KCL	350
13	Sucrose	400
14	Sorbitol	400

Supplementary Table 5: Identity of genes along with the type of mutation observed in the evolved osmotolerant strains E5 and H8 on genome sequencing (Related to Figure 8)

Strain	Gene	Type
H8	mngA	Ins del
H8	hyfB	Ins del
H8	fucl	Ins del
H8	kefC	missense
H8	sgrR	missense
H8	mraY	missense
H8	ftsW	missense
H8	dxs	missense
H8	cstA	stop

H8	mngA	missense
H8	clpA	missense
H8	flgL	missense
H8	oppB	missense
H8	uidR	missense
H8	otsA	missense
E5	mngA	Ins del
E5	csiR	Ins del
E5	fucl	Ins del
E5	rihC	missense
E5	lptD	missense
E5	mraY	missense
E5	malZ	stop
E5	cyoA	missense
E5	paaH	missense
E5	sdaA	missense